- March 15, 2022
- Newsletter
- 617-430-5616
Menu
» Home » Drug Database » Antibiotics, Antibacterials » Tetracyclines Q1 » doxycycline
ADVERTISEMENT
ADVERTISEMENT
» Home » Drug Database » Antibiotics, Antibacterials » Tetracyclines Q1 » doxycycline
Brand Name :
Doryx MPC, Adoxa, Periostat, Oracea, Doryx, Doxycin, Doxy, Avidoxy, Atridox, Acticlate, Monodox, Vibramycin
Synonyms :
doxycycline
Class :
Antibiotics & Tetracycline derivatives
Actions and Spectrum:
doxycycline is a broad-spectrum antibiotic that belongs to the tetracycline class of antibiotics. It is used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, skin infections, and sexually transmitted infections. Here are some of the actions and spectrum of doxycycline:
No drug interaction found for doxycycline and .
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
may diminish the absorption when combined with iron preparations
may diminish the absorption when combined with iron preparations
may diminish the absorption when combined with iron preparations
may diminish the absorption when combined with iron preparations
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
may diminish the absorption of iron preparations
may diminish the serum concentration when combined with tetracyclines
may diminish the serum concentration when combined with tetracyclines
may diminish the absorption of magnesium salts
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
aluminum hydroxide/magnesium carbonate
may decrease the serum concentration of antacids
aluminum hydroxide/magnesium carbonate
may decrease the serum concentration of antacids
may have a decreased therapeutic efficacy when combined with doxycycline
may increase the therapeutic efficacy of each other when combined
oral form of aluminum hydroxide inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
may enhance the toxic effects of doxycycline
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
interaction of both drugs may lead to respiratory depression
doxycycline may reduce the therapeutic effects of BCG vaccine
oral form of bismuth subsalicylate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium acetate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium carbonate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium chloride inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium citrate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
calcium gluconate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
calcium iron inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
doxycycline may reduce the therapeutic effects of cholera vaccine
doxycycline enhances the effects of cisatracurium
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
ferric meltol inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
ferrous fumarate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
ferrous gluconate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
ferrous sulfate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
iron dextran inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
iron sucrose inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
exhibit the risk of pseudotumor cerebri
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may increase risk of nephrotoxicity
it may enhance the photosensitizing effects of the other drug
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
interaction of both drugs may lead to respiratory depression
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects doxy
interaction of both drugs may lead to respiratory depression
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
interaction of both drugs may lead to respiratory depression
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
doxycycline can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
nafcillin will decrease the effect of action of doxycycline by antagonism.
Therapeutic efficacy of azlocillin may decrease.
bismuth subsalicylate reduces the levels of doxycycline by inhibiting gastrointestinal absorption
when both drugs are combined, there may be a decrease in levels of doxycycline
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with doxycycline it decreases the effects of action of drug by antagonism effect
amoxicillin and clavulanate potassium
when amoxicillin combines with doxycycline it decreases the effects of action of drug by antagonism effect
omeprazole amoxicillin and clarithromycin
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
cholestyramine reduces the therapeutic effects of doxycycline by inhibiting GI absorption
didanosine reduces the therapeutic effects of doxycycline by inhibiting GI absorption
doxycycline may interfere with the intestinal flora and reduce the effects of digoxin
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
estrogens conjugated synthetic
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
it reduces the therapeutic effects of doxycycline by inhibiting GI absorption
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
tetracycline reduces the therapeutic effects of methotrexate by suppressing GI metabolism by intestinal flora
increases the adverse toxic effects
increases the adverse toxic effects
doxycycline enhances the therapeutic effects of warfarin
zinc may reduce the GI absorption and effects of doxycycline
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
may reduce the therapeutic effect of penicillins
amoxicillin and clavulanate potassium
may reduce the therapeutic effect of penicillins
may reduce the therapeutic effect of penicillins
may reduce the therapeutic effect of penicillins
may reduce the therapeutic effect of penicillins
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
It may enhance the toxicity when combined with mipomersen
They may diminish the absorption when combined with bile acid sequestrants
It may enhance the effect when combined with cannabidiol by affecting CYP3A4 metabolism
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
piperacillin decreases the effectiveness of doxycycline by antagonism.
When bacampicillin combines with doxycycline, the effect and action of bacampicillin decreases.
When penicillin G benzathine combines with doxycycline, the action and effectiveness of penicillin G benzathine decreases.
when both drugs are combined, there may be a decreasing effect of ceftriaxone by pharmacodynamic antagonism
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may increase the hypoglycemic effect of sulfonylureas
may increase the hypoglycemic effect of sulfonylureas
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may diminish the absorption of magnesium salts
may diminish the absorption of magnesium salts
it may diminish the excretion rate when combined with corifollitropin alfa resulting in an enhanced serum level
doxycycline may enhance the therapeutic effects of antithrombin alfa
doxycycline may enhance the therapeutic effects of antithrombin III
doxycycline may enhance the therapeutic effects of argatoban
doxycycline may decrease the therapeutic effects of the balsalazide
doxycycline may decrease the therapeutic effects of the bemiparin
doxycycline may decrease the therapeutic effects of the biotin
doxycycline may increase the therapeutic effects of the bivalirudin
colestipol reduces the therapeutic effects of doxycycline by affecting GI absorption
doxycycline increases the effects of dalteparin by an unknown mechanism
doxycycline increases the effects of enoxaparin by an unknown mechanism
doxycycline increases the effects of fondaparinux by an unknown mechanism
doxycycline increases the effects of heparin by an unknown mechanism
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
Dosage Forms & Strengths
Capsule
50mg
75mg
100mg
150mg
Powder for reconstitution
100mg
Syrup
50mg/5ml
Oral Suspension
25mg/5ml
Tablet
20mg
50mg
75mg
100mg
150mg
Delayed release tablet
50mg
60mg
75mg
100mg
120mg
150mg
200mg
Delayed release capsule
40mg
Extended-release liquid
10%
Duration of <1 year:
100
mg
Orally
twice a day
2
weeks
Duration of ≥1 year: 100 mg Orally twice a day 4 weeks
200
mg
each day orally or intravenously divided twice daily
Intravenous dose can be once daily
Maintenance Dose
100-200 mg each day orally or intravenously divided twice daily
Intravenous dose can be once daily
200
mg
Orally
as a single dose
Dosage Forms & Strengths
Capsule
50mg
75mg
100mg
150mg
Powder for reconstitution
100mg
Syrup
50mg/5ml
Oral Suspension
25mg/5ml
Tablet
20mg
50mg
75mg
100mg
150mg
Delayed release tablet
50mg
60mg
75mg
100mg
120mg
150mg
200mg
Delayed release capsule
40mg
Extended-release liquid
10%
Children >8 years and adolescents: 50 to 100 mg orally once or twice a day (depends on the severity of infection and symptoms)
Infants, children, and adolescents:
4.4 mg/kg oral as a single dose (do not exceed 200mg/dose)
Children >8 years and adolescents:
1 to 2 mg/kg per dose twice a day for 10 days
Refer to adult dosing
Frequency not defined:
Esophageal ulcer
Increased liver enzymes
Visual disturbance
Dysphagia
Glossitis
Nausea
Vomiting
Diarrhea
Hepatotoxicity
Reversible and more frequent photosensitivity reaction
Dose-related diabetes insipidus
Discoloration of teeth
Superinfection, monilial
None
Contraindication/Caution:
doxycycline has several contraindications and cautions, including:
Pregnancy considerations: doxycycline can be assigned under pregnancy category D. Avoid during pregnancy.
Lactation: Doxycycline can be excreted in breast milk and may cause tooth discoloration in infants. Avoid use during breastfeeding.
Pregnancy category:
Pharmacology:
doxycycline is a broad-spectrum antibiotic that belongs to the tetracycline class of drugs. It works by inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA molecules to the mRNA-ribosome complex, and thereby blocking the elongation phase of protein synthesis. This ultimately leads to inhibition of bacterial growth and proliferation.
doxycycline has a long half-life of approximately 18-22 hours, which allows for less frequent dosing compared to other antibiotics. It is well absorbed after oral administration and reaches peak concentrations within 2-4 hours. It can also be administered intravenously in severe infections.
doxycycline has broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as against certain protozoa. It is commonly used to treat a wide range of infections, including respiratory tract infections, urinary tract infections, sexually transmitted infections, skin and soft tissue infections, and certain types of bacterial diarrhea.
Pharmacodynamics
The pharmacodynamics of doxycycline involve its ability to inhibit bacterial protein synthesis. doxycycline binds to the 30S ribosomal subunit of bacteria, preventing the attachment of aminoacyl-tRNA molecules to the mRNA-ribosome complex, and thereby blocking the elongation phase of protein synthesis. This ultimately leads to inhibition of bacterial growth and proliferation.
doxycycline has broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as against certain protozoa. Its bacteriostatic effect is concentration-dependent, meaning that higher concentrations of the drug are required to achieve a bactericidal effect. doxycycline is also effective against bacteria that are resistant to other antibiotics, including beta-lactam antibiotics.
In addition to its antibacterial activity, doxycycline has been shown to have anti-inflammatory and immunomodulatory effects. It has been suggested that doxycycline inhibits the production of pro-inflammatory cytokines and chemokines and may also modulate the activity of immune cells such as macrophages and T cells. These effects may contribute to its efficacy in the treatment of certain inflammatory conditions such as acne and rosacea.
Pharmacokinetics
Absorption
Completely absorbed orally, is reduced when taken with food or milk
The peak serum concentration is achieved in 1.5-4 hr
The bioavailability is reduced at high pH
Distribution
Protein-bound is 90%
Metabolism
It is metabolised in liver
Elimination and excretion
The half-life is achieved in 15-25 hours
The drug is excreted 23%in urine and 30% in feces
Administration:
doxycycline is an antibiotic that can be administered in several ways, depending on the intended use and severity of the infection:
Patient information leaflet
Generic Name: doxycycline
Pronunciation: DOX-i-SYE-kleen
Why do we use doxycycline?
doxycycline is a broad-spectrum antibiotic that is commonly used to treat bacterial infections, including sexually transmitted infections (STIs). The reason why doxycycline is often used for STIs is because it is effective against a variety of bacteria that can cause these infections, such as chlamydia, gonorrhea, and syphilis.
Chlamydia and gonorrhea are two of the most common STIs and are caused by bacterial infections. doxycycline is often used to treat these infections because it can target the bacteria responsible for the infections and stop them from replicating and spreading. Syphilis, another bacterial STI, can also be treated with doxycycline, especially in cases where penicillin (the preferred treatment) is not an option.
In addition to its effectiveness against bacterial STIs, doxycycline is also preferred because it is relatively safe, well-tolerated, and can be taken orally. It is also relatively affordable and widely available, making it a practical choice for treating STIs in many regions of the world.
ADVERTISEMENT
» Home » Drug Database » Antibiotics, Antibacterials » Tetracyclines Q1 » doxycycline
Brand Name :
Doryx MPC, Adoxa, Periostat, Oracea, Doryx, Doxycin, Doxy, Avidoxy, Atridox, Acticlate, Monodox, Vibramycin
Synonyms :
doxycycline
Class :
Antibiotics & Tetracycline derivatives
Dosage Forms & Strengths
Capsule
50mg
75mg
100mg
150mg
Powder for reconstitution
100mg
Syrup
50mg/5ml
Oral Suspension
25mg/5ml
Tablet
20mg
50mg
75mg
100mg
150mg
Delayed release tablet
50mg
60mg
75mg
100mg
120mg
150mg
200mg
Delayed release capsule
40mg
Extended-release liquid
10%
Duration of <1 year:
100
mg
Orally
twice a day
2
weeks
Duration of ≥1 year: 100 mg Orally twice a day 4 weeks
200
mg
each day orally or intravenously divided twice daily
Intravenous dose can be once daily
Maintenance Dose
100-200 mg each day orally or intravenously divided twice daily
Intravenous dose can be once daily
200
mg
Orally
as a single dose
Dosage Forms & Strengths
Capsule
50mg
75mg
100mg
150mg
Powder for reconstitution
100mg
Syrup
50mg/5ml
Oral Suspension
25mg/5ml
Tablet
20mg
50mg
75mg
100mg
150mg
Delayed release tablet
50mg
60mg
75mg
100mg
120mg
150mg
200mg
Delayed release capsule
40mg
Extended-release liquid
10%
Children >8 years and adolescents: 50 to 100 mg orally once or twice a day (depends on the severity of infection and symptoms)
Infants, children, and adolescents:
4.4 mg/kg oral as a single dose (do not exceed 200mg/dose)
Children >8 years and adolescents:
1 to 2 mg/kg per dose twice a day for 10 days
Refer to adult dosing